Clinical trials: Eye
Keratoconus
Assessing Patient Engagement in Keratoconus Clinical Research
This study aims to investigate the influences behind patient choices regarding involvement, discontinuation, or re-engagement in keratoconus clinical trials.
- Trial name
- NCT06288737
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Age-related Macular Degeneration
A Phase 1, Safety, Tolerability and Pharmacokinetic Profile of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) in Subjects With Neovascular Age-Related Macular Degeneration
The objectives of this study are to evaluate the safety, tolerability, and pharmacokinetic profile of E10030 intravitreous injection when administered as monotherapy or in combination with Lucentis® 0.5 mg/eye in subjects with…
- Trial name
- NCT00569140
- Testing
- E10030
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Ophthotech Corporation
Dry Age-related Macular Degeneration
A Study to Evaluate the Ocular Blood Flow Effects of Unoprostone Isopropyl in Adults With Dry Age-related Macular Degeneration
The purpose of this study is to determine the pharmacodynamics of ocular blood flow measurements with multiple drop unoprostone isopropyl administration versus placebo in subjects with dry age-related macular degeneration (AMD).
- Trial name
- NCT01379560
- Testing
- unoprostone isopropyl
- Where
- Austria
- Volunteers
- 33 people
- Sponsor
- Sucampo Pharma Americas, LLC
Long COVID
Study of Xiflam™ Treatment in Patients Post COVID-19 Infection Suffering From What is Known as Long COVID (LC)
The primary objective of this study is to evaluate the safety and efficacy of Xiflam versus Placebo in patients who present with signs and symptoms of Long COVID.
- Trial name
- NCT06437223
- Testing
- Tonabersat
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Inflammx Therapeutics Inc
Dry Eye
Efficacy and Safety of XG-104 for the Treatment of Dry Eye
The objective of this study is to assess the safety and efficacy of XG-104 Ophthalmic Solution compared to placebo for the treatment of the signs and symptoms of dry eye after a 4 week Three Times a Day (TID) treatment period
- Trial name
- NCT02235259
- Testing
- XG-104
- Where
- United States
- Volunteers
- 260 people
- Sponsor
- Xigen SA
Myopia, Progressive
Choroidal Response to Novel Spectacle Lens to Control Myopia Progression
Diurnal variations in the thickness of the choroid have been reported in the literature, and, more recently, the role of the choroid has been studied with respect to its role in myopia (near-sightedness) progression.
- Trial name
- CHERRY (NCT03818880)
- Testing
- Novel spectacle lens design
- Where
- Canada
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- SightGlass Vision, Inc.
Thyroid Eye Disease
A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease
A multicenter clinical study to evaluate the efficacy and safety of IBI311 in subjects with inactive thyroid eye disease. The study consists of two parts, with a maximum duration of approximately 64 weeks.
- Trial name
- NCT07113262
- Testing
- IBI311
- Where
- China
- Volunteers
- 111 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Myopia
A Two-Week Crossover Dispensing Evaluation Of Orion Daily Wear Soft Contact Lens
The primary objective of the study is to evaluate the clinical performance of test lens (Orion) in comparison with control lens (Gemini) over a period of two weeks of wear.
- Trial name
- NCT04585646
- Testing
- Orion daily disposable contact lens, Gemini daily disposable contact lens
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- CooperVision, Inc.
Dry Eye Disease (DED)
Dose-Finding Study of HUC1-394 in Participants With Dry Eye Disease
Clinical trial aims to determine the optimal dosing regimen by evaluating the efficacy and safety of HUC1-394 across different dosing frequencies in patients with moderate to severe dry eye disease.
- Trial name
- NCT07656688
- Testing
- HUC1-394
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- Huons Co., Ltd.
Retinitis Pigmentosa
A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa
The purpose of the study is to assess the safety and tolerability of bilateral subretinal delivery of adeno-associated virus vector with a serotype 5 capsid human rhodopsin kinase promoter.
- Trial name
- NCT05926583
- Testing
- AAV5-hRKp.RPGR
- Where
- Japan
- Volunteers
- 4 people
- Sponsor
- MeiraGTx Ocular UK Ltd
Non-24-Hour Sleep-Wake Disorder
Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder
The purpose of this study is to evaluate the maintenance effect and safety of 20 mg tasimelteon versus placebo in subjects suffering from Non-24-Hour Sleep-Wake Disorder.
- Trial name
- NCT01430754
- Testing
- tasimelteon
- Where
- 22 sites in United States
- Volunteers
- 20 people
- Sponsor
- Vanda Pharmaceuticals
Glaucoma
Chart Review of XEN 45 Gel Stent: Long Term Performance and Safety Assessment (XEN LT)
A retrospective, non-interventional, observational, multi-center, chart review study to be conducted in participants who underwent placement of the XEN 45 Gel Stent as a standalone procedure or in combination with…
- Trial name
- NCT03868254
- Testing
- XEN Group, Phacoemulsification
- Where
- United States
- Volunteers
- 174 people
- Sponsor
- Allergan
Geographic Atrophy
A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
This is a 24-month, Phase III, multicenter, randomized, double-masked, sham-injection controlled study to assess the efficacy and safety of multiple IVT injections of APL-2 in subjects with GA secondary to AMD.
- Trial name
- NCT03525613
- Testing
- APL-2
- Where
- 112 sites in United States, Australia and 12 more
- Volunteers
- 637 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Conjunctivitis, Seasonal Allergic, Conjunctivitis, Giant Papillary
A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5%
The objective of this study is to identify any adverse events or adverse drug reactions through post-marketing surveillance under routine clinical practice
- Conditions
- Conjunctivitis, Seasonal Allergic, Conjunctivitis, Giant Papillary, Inflammation
- Trial name
- NCT01437982
- Testing
- Loteprednol Etabonate, Prednisolone Acetate 1% Oph Susp
- Where
- South Korea
- Volunteers
- 140 people
- Sponsor
- Bausch & Lomb Incorporated
Geographic Atrophy Secondary to Age-related Macular Degeneration
Safety and Clinical Applicability of Transcorneal Electrical Stimulation (TES) in Geographic Atrophy
Geographic atrophy (GA) is a progressive eye disease that causes the degeneration of the retinal cells, particularly in the macula, leading to vision loss.
- Trial name
- TES-GAP (NCT07531927)
- Testing
- Transcorneal electrical stimulation (TES) with the OkuStim 2 System
- Where
- 5 sites in Germany
- Volunteers
- 70 people
- Sponsor
- Okuvision GmbH
Eye Diseases, Glaucoma, Open-Angle
Evaluation of the iStent Versus Two Ocular Hypotensive Agents in Patients With Primary Open-angle Glaucoma (POAG)
Prospective, unmasked, randomized evaluation of the iStent in patients with primary open-angle glaucoma. Patients will be randomized to one of two groups: 1) iStent, or 2) medication.
- Conditions
- Eye Diseases, Glaucoma, Open-Angle, Glaucoma
- Trial name
- SL (NCT00913029)
- Testing
- iStent, latanoprost/timolol
- Where
- 16 sites in Armenia, Austria and 7 more
- Volunteers
- 192 people
- Sponsor
- Glaukos Corporation
Dry Eye
Prospective Health Assessment of Cataract Patients' Ocular Surface
This study will determine the incidence and severity of dry eye in patients undergoing cataract surgery as determined by grade on the International Task Force (ITF) scale.
- Trial name
- NCT01016405
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Innovative Medical
Retinitis Pigmentosa
BS01 in Patients With Retinitis Pigmentosa
A Phase 1/2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP (AAV2-CAG-ChronosFP) in Patients with Retinitis Pigmentosa
- Trial name
- NCT04278131
- Testing
- BS01
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Bionic Sight LLC
Cataract
Safety and Efficacy of OMS302 in Subjects Undergoing Unilateral Cataract Extraction With Lens Replacement (CELR)
The purpose of this study is to determine whether the use of OMS302 (the study drug) in individuals undergoing Cataract Extraction with Lens Replacement (CELR) surgery is safe and effective at maintaining an adequately dilated…
- Trial name
- NCT01193127
- Testing
- OMS302 Solution, OMS302 Mydriatic Solution, OMS302 Anti-inflammatory Solution
- Where
- 24 sites in United States
- Volunteers
- 223 people
- Sponsor
- Omeros Corporation
Seasonal Allergic Conjunctivitis
A Study to Evaluate the Efficacy and Safety of Epinastine Hydrochloride Eye Drops in the Treatment of Chinese Seasonal Allergic Conjunctivitis Patients
The goal of this multicenter, randomized, double-blind, active control, non-inferiority clinical trial is to evaluate the efficacy of epinastine hydrochloride eye drops for the treatment of seasonal allergic conjunctivitis using…
- Trial name
- NCT06212973
- Testing
- Epinastine Hcl Oph Soln+Simulating Azelastine Hcl Oph Soln, Azelastine Hcl Oph Sol+Simulating Epinastine Hcl Oph Soln
- Where
- China
- Volunteers
- 266 people
- Sponsor
- Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.